Article Text

PDF
Extended report
Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1-year results of the COBRA-light open-label, randomised, non-inferiority trial
  1. Marieke M ter Wee1,
  2. Debby den Uyl1,
  3. Maarten Boers1,2,
  4. Pit Kerstens2,3,
  5. Mike Nurmohamed1,2,
  6. Dirkjan van Schaardenburg1,2,
  7. Alexandre E Voskuyl1,
  8. Willem F Lems1,2
  1. 1Department of Rheumatology, VU University Medical Center, Amsterdam, Noord Holland, The Netherlands
  2. 2Department of Rheumatology, Jan van Breemen Research Institute Reade, Amsterdam, Noord Holland, The Netherlands
  3. 3Westfriesgasthuis, Hoorn, Noord Holland, The Netherlands
  1. Correspondence to M M ter Wee, Department of Rheumatology, VU University Medical Center, Room 3A52, De Boelelaan 1117, Amsterdam 1081 HV, The Netherlands; m.terwee{at}vumc.nl

Abstract

Background Recently, we documented the likely non-inferiority of Combinatietherapie Bij Reumatoïde Artritis (COBRA)-light therapy (methotrexate increased to 25 mg/week with initial prednisolone 30 mg/day) compared with the original COBRA therapy (methotrexate 7.5 mg/week, sulfasalazine 2 g/day, with initial prednisolone 60 mg/day) after 26 weeks in patients with early active rheumatoid arthritis (RA).

Objective To assess the non-inferiority of COBRA-light versus COBRA after 1 year in terms of disease activity (DAS44), functional outcome (Health Assessment Questionnaire (HAQ)) and radiographic progression (Sharp/van der Heijde score (SHS)), and to assess the effect of adding etanercept.

Methods An open-label, randomised controlled, non-inferiority trial of 162 patients with active early RA, following a treat-to-target protocol incorporating the addition of etanercept if DAS44 ≥1.6 at weeks 26 or 39.

Results Both groups showed major improvements in DAS44 after 52 weeks: mean (SD) −2.41 (1.2) in the COBRA and −2.02 (1.0) in the COBRA-light group (p=ns). In both groups, functional ability improved and radiological progression of joints was minimal. At least one adverse event was reported in 96% of the patients in both groups. In total, 25 serious adverse events occurred: 9 vs 16 in COBRA and COBRA-light, respectively. Treatment actually instituted was often less intensive than required by the protocol: of the total population, 108 patients (67%) required etanercept (more in the COBRA-light group), but only 67 of these (62%) actually received it.

Conclusions Intensive COBRA or COBRA-light therapy has major, comparably favourable effects on disease activity, functional ability and radiological outcome after 1 year in patients with early RA. Protocolised addition of etanercept was often not implemented by treating rheumatologists, and patients receiving it appeared to have limited added benefit, probably because of low disease activity levels at its initiation.

Trial registration number: ISRCTN55552928.

  • Early Rheumatoid Arthritis
  • Anti-TNF
  • DMARDs (synthetic)
  • Outcomes research
  • Treatment

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.